---
title: "Psych News Alert: Adjunctive Intranasal Esketamine Rapidly Decreases Depression Symptoms"
description: Intranasal esketamine taken twice weekly can rapidly reduce symptoms of people with treatment-resistant depression, according to a study ...
image: https://alert.psychnews.org/hubfs/Imported_Blog_Media/nasal_spray_iStock-184294958-Jun-24-2025-05-19-01-1520-PM.jpg
---

 1/8/18 12:00 AM

# Adjunctive Intranasal Esketamine Rapidly Decreases Depression Symptoms

![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [ Psychiatric News Alert ](https://alert.psychnews.org/author/psychiatric-news-alert)

Share: [facebook-f icon ](http://www.facebook.com/share.php?u=https://alert.psychnews.org/2018/01/adjunctive-intranasal-esketamine.html) [linkedin-in icon ](http://www.linkedin.com/shareArticle?mini=true&url=https://alert.psychnews.org/2018/01/adjunctive-intranasal-esketamine.html) [Twitter icon ](https://twitter.com/intent/tweet?url=https://alert.psychnews.org/2018/01/adjunctive-intranasal-esketamine.html) [pinterest-p icon ](http://pinterest.com/pin/create/link/?url=https://alert.psychnews.org/2018/01/adjunctive-intranasal-esketamine.html) [envelope icon ](mailto:?body=https://alert.psychnews.org/2018/01/adjunctive-intranasal-esketamine.html)

| ![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/nasal_spray_iStock-184294958-Jun-24-2025-05-18-59-6596-PM.jpg?width=133&height=200&name=nasal_spray_iStock-184294958-Jun-24-2025-05-18-59-6596-PM.jpg) |  |
| --- | --- |

Intranasal esketamine taken twice weekly can rapidly reduce symptoms of people with treatment-resistant depression, according to a [study](https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2666767) in *JAMA Psychiatry*.

Esketamine is the mirror image molecule of ketamine. The two molecules are very similar biologically, but esketamine is reported to produce fewer psychomimetic side effects like delirium or hallucinations.

Ella Daly, M.D., of Janssen Research and Development and colleagues recruited 67 adults with treatment-resistant depression; treatment resistance was defined as having a history of inadequate response to two or more antidepressants. The patients were randomly divided so that half received placebo while the other half received 28 mg, 56 mg, or 84 mg of esketamine twice weekly for two weeks. All participants continued the antidepressants they were receiving at study entry during the trial.

The researchers found that all three esketamine doses produced significantly greater reductions in the participants’ Montgomery-Asberg Depression Rating Scale scores from baseline after one week. The improvements escalated with dose, with 4.2, 6.3, and 9.0-point improvements for the 28 mg, 56 mg, and 84 mg doses, respectively.

After 15 days, all participants were invited to enroll in a 60-day open-label period, during which they received esketamine twice weekly for two weeks, weekly for three weeks, and then every two weeks thereafter. The improvements in depressive symptoms were maintained during the open-label period despite the reduced dosing frequency, and for up to two months after the discontinuation of esketamine.

“In general, the esketamine doses used in this study appeared to be safe, with no new or unexpected safety concerns observed,” the authors wrote. “Overall, transient increases in blood pressure after the dose, particularly increases in systolic blood pressure, support an increase in cardiac output as the underlying mechanism, consistent with previous reports of ketamine.”

To read more about this topic, see the *Psychiatric News* article “[Ketamine Is a Potent Antidepressant, but How Does It Work?](https://psychnews.psychiatryonline.org/doi/full/10.1176/appi.pn.2017.8a3)”

(Image: iStock/zoljo)

[ketamine](https://alert.psychnews.org/tag/ketamine), [treatment-resistant depression](https://alert.psychnews.org/tag/treatment-resistant-depression), [esketamine](https://alert.psychnews.org/tag/esketamine), [Montgomery-Åsberg Depression Rating](https://alert.psychnews.org/tag/montgomery-åsberg-depression-rating), [Janssen](https://alert.psychnews.org/tag/janssen), [Ella Daly](https://alert.psychnews.org/tag/ella-daly)

## Related posts

[![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/IV%20drip_iStock_00002009034-Jun-24-2025-03-52-30-1371-PM.jpg?height=200&name=IV%20drip_iStock_00002009034-Jun-24-2025-03-52-30-1371-PM.jpg) ](https://alert.psychnews.org/2016/05/ketamine-may-reduce-active-suicidal.html)

[suicide](https://alert.psychnews.org/tag/suicide), [ketamine](https://alert.psychnews.org/tag/ketamine), [depression](https://alert.psychnews.org/tag/depression), [suicidal ideation](https://alert.psychnews.org/tag/suicidal-ideation), [depression treatment](https://alert.psychnews.org/tag/depression-treatment)

## [Ketamine May Reduce Active Suicidal Thoughts in Patients With Treatment-Resistant Depression](https://alert.psychnews.org/2016/05/ketamine-may-reduce-active-suicidal.html)

![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [Psychiatric News Alert](https://alert.psychnews.org/author/psychiatric-news-alert) 

 6/24/24 11:16 AM

Ketamine may be able to rapidly reduce persistent suicidal thoughts in medicated patients with...

[ Read more ](https://alert.psychnews.org/2016/05/ketamine-may-reduce-active-suicidal.html)

[![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/KETAMINE_HYDROCHLORIDE_050_32-72983_1-Jun-24-2025-10-33-48-4076-PM.jpg?height=200&name=KETAMINE_HYDROCHLORIDE_050_32-72983_1-Jun-24-2025-10-33-48-4076-PM.jpg) ](https://alert.psychnews.org/2013/08/ketamine-may-be-beneficial-in-treatment.html)

[ketamine](https://alert.psychnews.org/tag/ketamine), [treatment-resistant depression](https://alert.psychnews.org/tag/treatment-resistant-depression), [psychopharmacology](https://alert.psychnews.org/tag/psychopharmacology)

## [Ketamine May Be Beneficial in Treatment-Resistant Depression, Study Finds](https://alert.psychnews.org/2013/08/ketamine-may-be-beneficial-in-treatment.html)

![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [Psychiatric News Alert](https://alert.psychnews.org/author/psychiatric-news-alert) 

 8/28/13 12:00 AM

Pursuing effective therapies to alleviate treatment-resistant depression can be challenging for...

[ Read more ](https://alert.psychnews.org/2013/08/ketamine-may-be-beneficial-in-treatment.html)

[![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/emergency_iStock_000058321222_Small-Jun-24-2025-03-45-06-6120-PM.jpg?height=200&name=emergency_iStock_000058321222_Small-Jun-24-2025-03-45-06-6120-PM.jpg) ](https://alert.psychnews.org/2019/11/ketamine-found-to-rapidly-reduce.html)

[suicide](https://alert.psychnews.org/tag/suicide), [ketamine](https://alert.psychnews.org/tag/ketamine), [depression](https://alert.psychnews.org/tag/depression), [blood pressure](https://alert.psychnews.org/tag/blood-pressure), [emergency department](https://alert.psychnews.org/tag/emergency-department), [dissociative effects](https://alert.psychnews.org/tag/dissociative-effects), [Yoav Domany](https://alert.psychnews.org/tag/yoav-domany)

## [Ketamine Found to Rapidly Reduce Suicidal Thoughts in Depressed, Suicidal Patients in ER](https://alert.psychnews.org/2019/11/ketamine-found-to-rapidly-reduce.html)

![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [Psychiatric News Alert](https://alert.psychnews.org/author/psychiatric-news-alert) 

 6/24/24 11:16 AM

Patients presenting to an emergency room with complaints of suicidal thoughts may experience relief...

[ Read more ](https://alert.psychnews.org/2019/11/ketamine-found-to-rapidly-reduce.html)

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Psychiatric News Alert",
    "url" : "https://alert.psychnews.org/author/psychiatric-news-alert"
  },
  "dateModified" : "2025-06-24T17:22:55.464Z",
  "datePublished" : "2018-01-08T05:00:00.000Z",
  "headline" : "Psych News Alert: Adjunctive Intranasal Esketamine Rapidly Decreases Depression Symptoms",
  "image" : [ "https://alert.psychnews.org/hubfs/Imported_Blog_Media/nasal_spray_iStock-184294958-Jun-24-2025-05-19-01-1520-PM.jpg" ],
  "mainEntityOfPage" : {
    "@id" : "https://alert.psychnews.org/2018/01/adjunctive-intranasal-esketamine.html",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://alert.psychnews.org/hubfs/PN-Blue-Box.jpg"
    }
  }
}
```